首页 > 最新文献

Acta Clinica Belgica最新文献

英文 中文
Assessing ciliary function in polycystic kidney disease: beyond the kidney. 多囊肾病的纤毛功能评估:肾脏以外。
IF 0.9 4区 医学 Q2 Medicine Pub Date : 2025-12-01 Epub Date: 2025-10-29 DOI: 10.1080/17843286.2025.2581284
Beyza Doğan, Fatih Ergül, Mikail Dağ, Süleyman Karaköse, Latif Emre Özdemir, Abitter Yücel, İbrahim Güney

Background: This study sought to investigate the effects of polycystic kidney disease and tolvaptan administration on mucociliary clearance.

Methods: The cross-sectional study enrolled 30 patients with autosomal dominant polycystic kidney disease undergoing tolvaptan therapy, 30 patients with autosomal dominant polycystic kidney disease not on tolvaptan, and 30 healthy volunteers. Nasal mucociliary clearance time was determined using the saccharin transit time test, with a 1 mm diameter saccharin particle carefully placed on the anteromedial surface of the inferior nasal concha. Comparisons of mucociliary clearance time were then performed between the groups.

Results: In our study, the average mucociliary clearance time for patients with polycystic kidney disease was determined to be 9, in contrast to an average of 11 in the control group. A comparative analysis of patients receiving tolvaptan and those not receiving tolvaptan revealed an identical average mucociliary clearance time of 9 for both cohorts (p = 0.706). Furthermore, patients treated with tolvaptan demonstrated an average urine specific gravity of 1004, significantly lower than the 1011 observed in the non-tolvaptan group (p = 0.001).

Conclusion: This study indicates that the administration of tolvaptan yielded a beneficial impact on hydration status; however, this improved hydration did not translate into a significant effect on mucociliary clearance. Furthermore, the mucociliary clearance times recorded in the patient group were found to be in alignment with those typically associated with chronic kidney disease cohorts.

背景:本研究旨在探讨多囊肾病和托伐普坦对粘膜纤毛清除的影响。方法:横断面研究纳入30例接受托伐普坦治疗的常染色体显性多囊肾病患者,30例未接受托伐普坦治疗的常染色体显性多囊肾病患者和30名健康志愿者。采用糖精传递时间试验测定鼻黏膜纤毛清除时间,将直径为1 mm的糖精颗粒小心放置于下鼻甲前内侧表面。比较两组间纤毛粘液清除时间。结果:在我们的研究中,多囊肾病患者的平均粘膜纤毛清除时间为9,而对照组的平均清除时间为11。一项接受托伐普坦治疗和未接受托伐普坦治疗的患者的比较分析显示,两组患者的平均黏毛清除时间相同,均为9小时(p = 0.706)。此外,接受托伐普坦治疗的患者平均尿比重为1004,显著低于未接受托伐普坦治疗组的1011 (p = 0.001)。结论:本研究表明,托伐普坦对水化状态有有益影响;然而,这种改善的水合作用并没有转化为对黏毛清除的显著影响。此外,在患者组中记录的黏液纤毛清除时间被发现与那些典型的与慢性肾脏疾病相关的队列一致。
{"title":"Assessing ciliary function in polycystic kidney disease: beyond the kidney.","authors":"Beyza Doğan, Fatih Ergül, Mikail Dağ, Süleyman Karaköse, Latif Emre Özdemir, Abitter Yücel, İbrahim Güney","doi":"10.1080/17843286.2025.2581284","DOIUrl":"10.1080/17843286.2025.2581284","url":null,"abstract":"<p><strong>Background: </strong>This study sought to investigate the effects of polycystic kidney disease and tolvaptan administration on mucociliary clearance.</p><p><strong>Methods: </strong>The cross-sectional study enrolled 30 patients with autosomal dominant polycystic kidney disease undergoing tolvaptan therapy, 30 patients with autosomal dominant polycystic kidney disease not on tolvaptan, and 30 healthy volunteers. Nasal mucociliary clearance time was determined using the saccharin transit time test, with a 1 mm diameter saccharin particle carefully placed on the anteromedial surface of the inferior nasal concha. Comparisons of mucociliary clearance time were then performed between the groups.</p><p><strong>Results: </strong>In our study, the average mucociliary clearance time for patients with polycystic kidney disease was determined to be 9, in contrast to an average of 11 in the control group. A comparative analysis of patients receiving tolvaptan and those not receiving tolvaptan revealed an identical average mucociliary clearance time of 9 for both cohorts (<i>p</i> = 0.706). Furthermore, patients treated with tolvaptan demonstrated an average urine specific gravity of 1004, significantly lower than the 1011 observed in the non-tolvaptan group (<i>p</i> = 0.001).</p><p><strong>Conclusion: </strong>This study indicates that the administration of tolvaptan yielded a beneficial impact on hydration status; however, this improved hydration did not translate into a significant effect on mucociliary clearance. Furthermore, the mucociliary clearance times recorded in the patient group were found to be in alignment with those typically associated with chronic kidney disease cohorts.</p>","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"186-192"},"PeriodicalIF":0.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145385801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the real-life value of first responders for out-of-hospital cardiac arrest in a Belgian urban context: a retrospective analysis. 在比利时城市背景下,探索院外心脏骤停急救人员的现实价值:回顾性分析。
IF 0.9 4区 医学 Q2 Medicine Pub Date : 2025-10-01 Epub Date: 2025-10-13 DOI: 10.1080/17843286.2025.2573748
P Van de Voorde, M Du Bois, T Tackaert, K To, N Mpotos

Aim: First Responder [FR] systems are associated with improved outcomes. However, this evidence has very low certainty. We aimed to explore - using real-life data - the reality of out-of-hospital cardiac arrest [OHCA] in a Belgian municipal region where there currently is no such system.

Methods: We explored the hypothetical potential for an FR in all cases of OHCA attended by the physician-staffed emergency medical services [EMS] team of Ghent University Hospital [07/2020-06/2021].

Results: Of the 200 attended cases, 76% were residential; 54% were unwitnessed. Bystander CPR occurred in 36.5%, a public-access AED was used in only three cases. Eleven patients survived beyond hospital discharge, all but one with good neurological outcomes. In 60%, we considered an FR obsolete from start (due to irreversible death, existing advance directive, resourceful setting, early EMS arrival, OHCA not recognized, or EMS witnessed). Another 10% were traumatic OHCA, a category universally excluded. Although impossible to identify those cases from the remaining 30% (n = 60) that would truly benefit, the actual number is likely far lower due to a.o. the likelihood of prolonged no-flow in unwitnessed residential OHCA (one-third or complicating contexts, victim accessibility, or FR availability).

Conclusion: There might be added value for an FR system in selected populations, but the associated cost-effectiveness ratios and the potential for harm should not be ignored. Better identification of victims potentially benefitting at the system point of entry is crucial.

目的:第一响应者(FR)系统与改善预后相关。然而,这一证据的确定性非常低。我们的目的是探索-使用现实生活中的数据-医院外心脏骤停[OHCA]的现实在比利时市区,目前没有这样的系统。方法:我们探讨了根特大学医院急诊医疗服务(EMS)团队在2020年7月至2021年6月期间就诊的所有OHCA病例发生FR的假设可能性。结果:在200例就诊病例中,76%是住院患者;54%无人目击。36.5%的人使用了旁观者CPR,只有3例使用了公共AED。11名患者在出院后存活下来,除1名患者外,其余患者的神经系统预后良好。在60%的病例中,我们认为FR从一开始就过时了(由于不可逆转的死亡、现有的预先指示、资源充足的环境、早期的EMS到达、未识别的OHCA或EMS目击)。另外10%是创伤性职业倦怠症,这一类别被普遍排除在外。虽然不可能从剩余的30% (n = 60)中识别出真正受益的病例,但实际数字可能要低得多,因为a.o.在未目击的住宅OHCA中长期无流动的可能性(三分之一或复杂的情况,受害者可及性或FR可用性)。结论:FR系统在特定人群中可能有附加价值,但相关的成本-效果比和潜在危害不应被忽视。在系统入境点更好地识别可能受益的受害者至关重要。
{"title":"Exploring the real-life value of first responders for out-of-hospital cardiac arrest in a Belgian urban context: a retrospective analysis.","authors":"P Van de Voorde, M Du Bois, T Tackaert, K To, N Mpotos","doi":"10.1080/17843286.2025.2573748","DOIUrl":"10.1080/17843286.2025.2573748","url":null,"abstract":"<p><strong>Aim: </strong>First Responder [FR] systems are associated with improved outcomes. However, this evidence has very low certainty. We aimed to explore - using real-life data - the reality of out-of-hospital cardiac arrest [OHCA] in a Belgian municipal region where there currently is no such system.</p><p><strong>Methods: </strong>We explored the hypothetical potential for an FR in all cases of OHCA attended by the physician-staffed emergency medical services [EMS] team of Ghent University Hospital [07/2020-06/2021].</p><p><strong>Results: </strong>Of the 200 attended cases, 76% were residential; 54% were unwitnessed. Bystander CPR occurred in 36.5%, a public-access AED was used in only three cases. Eleven patients survived beyond hospital discharge, all but one with good neurological outcomes. In 60%, we considered an FR obsolete from start (due to irreversible death, existing advance directive, resourceful setting, early EMS arrival, OHCA not recognized, or EMS witnessed). Another 10% were traumatic OHCA, a category universally excluded. Although impossible to identify those cases from the remaining 30% (<i>n</i> = 60) that would truly benefit, the actual number is likely far lower due to a.o. the likelihood of prolonged no-flow in unwitnessed residential OHCA (one-third or complicating contexts, victim accessibility, or FR availability).</p><p><strong>Conclusion: </strong>There might be added value for an FR system in selected populations, but the associated cost-effectiveness ratios and the potential for harm should not be ignored. Better identification of victims potentially benefitting at the system point of entry is crucial.</p>","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"159-165"},"PeriodicalIF":0.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145285309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emerging threat of WHO priority pathogens in ICU-associated CLABSI and CAUTI: an integrated analysis of resistance patterns, epidemiological trends, and stewardship strategies. icu相关CLABSI和CAUTI中世卫组织重点病原体的新威胁:耐药性模式、流行病学趋势和管理策略的综合分析
IF 0.9 4区 医学 Q2 Medicine Pub Date : 2025-10-01 Epub Date: 2025-08-17 DOI: 10.1080/17843286.2025.2546420
Gargee Anand, Rijhul Lahariya, Ketan Priyadarshi, Asim Sarfraz

Purpose: To unmask the alarming prevalence, intricate antimicrobial resistance patterns, and consequential clinical outcomes of World Health Organization (WHO) priority pathogens causing device-associated infections in critical care settings - a frontier analysis of silent pandemic threatening modern healthcare.

Methods: This groundbreaking retrospective study analysed data from 5,398 patients at risk for central line-associated bloodstream infections (CLABSI) and 15,416 patients for catheter-associated urinary tract infections (CAUTI) spanning 2021-2024. Microbial isolates were categorized according to WHO's priority pathogen classifications. Antimicrobial susceptibility profiles were comprehensively analysed using Clinical and Laboratory Standards Institute guidelines, with statistical analyses elucidating pathogen distribution dynamics, resistance mechanisms, and mortality correlations.

Results: Striking findings revealed WHO priority pathogens dominated the microbial landscape, constituting 76.47% of CLABSI and 82.14% of CAUTI isolates - with critical priority organisms overwhelmingly predominant (83.34% and 91.3%, respectively). Carbapenem-resistant Enterobacterales (CRE) emerged as the formidable leading threat (39.5% of CLABSI, 72.7% of CAUTI), while Carbapenem-resistant Acinetobacter baumannii (CRAB) demonstrated exceptional virulence with devastating mortality (93.33%). The study unveiled unprecedented levels of multidrug resistance, with most therapeutic options rendered ineffective; only colistin maintained universal efficacy against gram-negative isolates despite its concerning toxicity profile. Dramatic disparities in infection outcomes revealed CLABSI-associated mortality rates (71.79%) significantly eclipsed CAUTI (39.13%), establishing infection type as a critical independent predictor of survival.

Conclusions: This landmark investigation exposes the crossroad between WHO priority pathogens and healthcare-associated infections, sounding an urgent alarm for global healthcare systems. Our findings provide crucial evidence-based guidance for recalibrating therapeutic approaches, optimizing antimicrobial selection, and prioritizing infection control measures in intensive care settings worldwide.

目的:揭示在重症监护环境中引起器械相关感染的世界卫生组织(WHO)优先病原体的惊人流行、复杂的抗菌素耐药性模式和相应的临床结果——对威胁现代医疗保健的无声大流行的前沿分析。方法:这项开创性的回顾性研究分析了2021-2024年间5398例中心线相关血流感染(CLABSI)风险患者和15416例导管相关尿路感染(CAUTI)患者的数据。微生物分离物根据世卫组织的重点病原体分类进行分类。根据临床和实验室标准协会的指南,对抗菌药物敏感性进行全面分析,并通过统计分析阐明病原体分布动态、耐药机制和死亡率相关性。结果:令人震惊的发现显示,WHO重点病原体在微生物景观中占主导地位,占CLABSI的76.47%和CAUTI分离株的82.14%,其中关键重点微生物占绝大多数(分别为83.34%和91.3%)。耐碳青霉烯肠杆菌(CRE)是最主要的威胁(CLABSI的39.5%,CAUTI的72.7%),而耐碳青霉烯鲍曼不动杆菌(CRAB)表现出异常的毒力和毁灭性的死亡率(93.33%)。该研究揭示了前所未有的多药耐药水平,大多数治疗方案无效;只有粘菌素对革兰氏阴性分离株具有普遍的药效,尽管其毒性较低。感染结果的巨大差异显示clabsi相关死亡率(71.79%)显著超过CAUTI(39.13%),将感染类型确定为生存的关键独立预测因子。结论:这项具有里程碑意义的调查揭示了世卫组织重点病原体与卫生保健相关感染之间的十字路口,为全球卫生保健系统敲响了紧急警报。我们的研究结果为重新校准治疗方法、优化抗菌药物选择以及在全球重症监护环境中优先考虑感染控制措施提供了重要的循证指导。
{"title":"Emerging threat of WHO priority pathogens in ICU-associated CLABSI and CAUTI: an integrated analysis of resistance patterns, epidemiological trends, and stewardship strategies.","authors":"Gargee Anand, Rijhul Lahariya, Ketan Priyadarshi, Asim Sarfraz","doi":"10.1080/17843286.2025.2546420","DOIUrl":"10.1080/17843286.2025.2546420","url":null,"abstract":"<p><strong>Purpose: </strong>To unmask the alarming prevalence, intricate antimicrobial resistance patterns, and consequential clinical outcomes of World Health Organization (WHO) priority pathogens causing device-associated infections in critical care settings - a frontier analysis of silent pandemic threatening modern healthcare.</p><p><strong>Methods: </strong>This groundbreaking retrospective study analysed data from 5,398 patients at risk for central line-associated bloodstream infections (CLABSI) and 15,416 patients for catheter-associated urinary tract infections (CAUTI) spanning 2021-2024. Microbial isolates were categorized according to WHO's priority pathogen classifications. Antimicrobial susceptibility profiles were comprehensively analysed using Clinical and Laboratory Standards Institute guidelines, with statistical analyses elucidating pathogen distribution dynamics, resistance mechanisms, and mortality correlations.</p><p><strong>Results: </strong>Striking findings revealed WHO priority pathogens dominated the microbial landscape, constituting 76.47% of CLABSI and 82.14% of CAUTI isolates - with critical priority organisms overwhelmingly predominant (83.34% and 91.3%, respectively). Carbapenem-resistant Enterobacterales (CRE) emerged as the formidable leading threat (39.5% of CLABSI, 72.7% of CAUTI), while Carbapenem-resistant <i>Acinetobacter baumannii</i> (CRAB) demonstrated exceptional virulence with devastating mortality (93.33%). The study unveiled unprecedented levels of multidrug resistance, with most therapeutic options rendered ineffective; only colistin maintained universal efficacy against gram-negative isolates despite its concerning toxicity profile. Dramatic disparities in infection outcomes revealed CLABSI-associated mortality rates (71.79%) significantly eclipsed CAUTI (39.13%), establishing infection type as a critical independent predictor of survival.</p><p><strong>Conclusions: </strong>This landmark investigation exposes the crossroad between WHO priority pathogens and healthcare-associated infections, sounding an urgent alarm for global healthcare systems. Our findings provide crucial evidence-based guidance for recalibrating therapeutic approaches, optimizing antimicrobial selection, and prioritizing infection control measures in intensive care settings worldwide.</p>","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"135-145"},"PeriodicalIF":0.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144870809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evolution of muscle mass and strength in patients admitted for a diabetic foot ulcer. 糖尿病足溃疡患者肌肉质量和力量的演变。
IF 0.9 4区 医学 Q2 Medicine Pub Date : 2025-10-01 Epub Date: 2025-08-21 DOI: 10.1080/17843286.2025.2543334
Yenna Hulshagen, Janne Terwingen, Dorien Frings, An Verrijken, Kristof Van Dessel, Carolien Van Gils, Ilse De Peuter, Patrick Lauwers, Eveline Dirinck

Objective: This study aimed to assess changes in muscle mass and strength in patients hospitalized due to a diabetic foot ulcer, and to evaluate the impact of malnutrition at admission on these parameters.

Methods: This prospective observational cohort study included patients from February 2021 to July 2024. Anthropometric measurements, handgrip strength tests, and impedance analyses were conducted. Diagnosis of malnutrition was based on the Global Leadership Initiative on Malnutrition criteria. All patients received nutritional support during their hospital stay.

Results: Seventy-eight DFU patients (74% men, median age 72 years, median BMI 27.6 kg/m2) were recruited. Half of them was malnourished. Median hospital stay was 28 days. Overall, muscle mass and handgrip strength at admission and discharge did not differ significantly (18.31 ± 2.05 versus 18.08 ± 2.11 kg/m2 and 26.02 ± 10.27 versus 26.45 ± 11.45 kg respectively). At admission, muscle mass was 17.25 ± 1.66 kg/m2 in malnourished patients versus 19.37 ± 1.85 kg/m2 in non-malnourished patients (p < 0.001), muscle strength was 24.82 ± 9.39 kg versus 27.23 ± 11.07 kg respectively (non-significant). Muscle mass change in malnourished patients was -0.039 ± 1.35 versus -0.562 ± 1.21 kg/m2 for non-malnourished. Muscle strength change for malnourished patients was 0.4 (-8.3 to 15) and 0 (-2.90 to 2.70) kg for non-malnourished. Both changes were not significantly different.

Conclusion: DFU Patients exhibited no significant changes in muscle mass or strength during hospitalization, regardless of nutritional status at admission. Malnutrition did not significantly affect changes in muscle mass or strength during hospitalization. These findings indicate that the current clinical approach including nutritional counselling and support, appears to stabilize muscle health in this relatively immobile and fragile population.

目的:本研究旨在评估糖尿病足溃疡住院患者肌肉质量和力量的变化,并评估入院时营养不良对这些参数的影响。方法:该前瞻性观察队列研究纳入了2021年2月至2024年7月的患者。进行了人体测量、握力测试和阻抗分析。营养不良的诊断依据的是营养不良全球领导倡议的标准。所有患者在住院期间均接受营养支持。结果:78例DFU患者(74%男性,中位年龄72岁,中位BMI 27.6 kg/m2)被招募。其中一半人营养不良。平均住院时间为28天。总的来说,入院和出院时的肌肉质量和握力没有显著差异(分别为18.31±2.05 vs 18.08±2.11 kg/m2和26.02±10.27 vs 26.45±11.45 kg)。入院时,营养不良患者的肌肉质量为17.25±1.66 kg/m2,非营养不良患者为19.37±1.85 kg/m2 (p < 2)。营养不良患者的肌力变化为0.4 (-8.3 ~ 15)kg,非营养不良患者的肌力变化为0 (-2.90 ~ 2.70)kg。两者变化无显著性差异。结论:无论入院时的营养状况如何,DFU患者在住院期间肌肉质量或力量均无显著变化。在住院期间,营养不良对肌肉质量或力量的变化没有显著影响。这些发现表明,目前的临床方法,包括营养咨询和支持,似乎可以稳定这些相对不活动和脆弱人群的肌肉健康。
{"title":"Evolution of muscle mass and strength in patients admitted for a diabetic foot ulcer.","authors":"Yenna Hulshagen, Janne Terwingen, Dorien Frings, An Verrijken, Kristof Van Dessel, Carolien Van Gils, Ilse De Peuter, Patrick Lauwers, Eveline Dirinck","doi":"10.1080/17843286.2025.2543334","DOIUrl":"10.1080/17843286.2025.2543334","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to assess changes in muscle mass and strength in patients hospitalized due to a diabetic foot ulcer, and to evaluate the impact of malnutrition at admission on these parameters.</p><p><strong>Methods: </strong>This prospective observational cohort study included patients from February 2021 to July 2024. Anthropometric measurements, handgrip strength tests, and impedance analyses were conducted. Diagnosis of malnutrition was based on the Global Leadership Initiative on Malnutrition criteria. All patients received nutritional support during their hospital stay.</p><p><strong>Results: </strong>Seventy-eight DFU patients (74% men, median age 72 years, median BMI 27.6 kg/m<sup>2</sup>) were recruited. Half of them was malnourished. Median hospital stay was 28 days. Overall, muscle mass and handgrip strength at admission and discharge did not differ significantly (18.31 ± 2.05 versus 18.08 ± 2.11 kg/m<sup>2</sup> and 26.02 ± 10.27 versus 26.45 ± 11.45 kg respectively). At admission, muscle mass was 17.25 ± 1.66 kg/m<sup>2</sup> in malnourished patients versus 19.37 ± 1.85 kg/m<sup>2</sup> in non-malnourished patients (<i>p</i> < 0.001), muscle strength was 24.82 ± 9.39 kg versus 27.23 ± 11.07 kg respectively (non-significant). Muscle mass change in malnourished patients was -0.039 ± 1.35 versus -0.562 ± 1.21 kg/m<sup>2</sup> for non-malnourished. Muscle strength change for malnourished patients was 0.4 (-8.3 to 15) and 0 (-2.90 to 2.70) kg for non-malnourished. Both changes were not significantly different.</p><p><strong>Conclusion: </strong>DFU Patients exhibited no significant changes in muscle mass or strength during hospitalization, regardless of nutritional status at admission. Malnutrition did not significantly affect changes in muscle mass or strength during hospitalization. These findings indicate that the current clinical approach including nutritional counselling and support, appears to stabilize muscle health in this relatively immobile and fragile population.</p>","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"123-134"},"PeriodicalIF":0.9,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144938388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Short-term CGM as a tool to optimize glycemic control and defer intensive insulin therapy in people with poorly controlled type 2 diabetes: a Belgian real-life study. 短期CGM作为优化血糖控制和延迟2型糖尿病患者强化胰岛素治疗的工具:比利时的一项现实研究
IF 0.9 4区 医学 Q2 Medicine Pub Date : 2025-08-01 Epub Date: 2025-07-03 DOI: 10.1080/17843286.2025.2528030
Philippe Oriot, Linh Bui, Noémie Klipper Dit Kurz, Mirela Morisca Gavriliu, Maria-Claudia Negrea, Michel P Hermans

Objective: Continuous glucose monitoring (CGM) benefits type 2 diabetes (T2D) patients on multiple daily insulin injections (MDI), but its role in non-intensive insulin therapy remains underexplored. This study evaluates whether a short-term CGM non-blinded can postpone the escalation to multiple daily insulin injections in people with poorly controlled T2D.

Methods: This retrospective real-world study analyzed data from 309 adults with T2D in primary care who used a 10 or 14-day CGM (2020-2024). The primary objective was to assess CGM's impact on therapy escalation, particularly to MDI. The secondary objective was to identify factors predicting the intensification of glucose-lowering therapy (GLT).

Results: Among the 309 participants (median age: 65 [56-73] years, diabetes duration: 16 [11-23] years, baseline HbA1c: 8.6% [70 mmol/mol]), 91.3% were deemed unsuitable for MDI based on CGM results (non-MDI GLT group, n = 282). In this group, 76% achieved an HbA1c-GMI differential > 0.5%, and 54% >1.0% after 14 day-CGM. Basal insulin use decreased slightly (70% to 64%, p = 0.13), while twice-daily insulin increased (12% to 18%, p = 0.02). GLTs remained largely unchanged.

Conclusion: A short-term CGM prevented MDI escalation in 91.3% of poorly controlled T2D adults, reinforcing its role as a cost-effective strategy. CGM likely improved self-management behaviors, as evidenced by frequent HbA1c-GMI differentials, reflecting better management of hyperglycemia. These findings highlight CGM as a practical behavioral and therapeutic tool in diabetes care.

目的:持续血糖监测(CGM)对2型糖尿病(T2D)患者每日多次胰岛素注射(MDI)有益,但其在非强化胰岛素治疗中的作用尚不清楚。本研究评估短期非盲CGM是否可以延缓t2dm控制不良患者每日多次胰岛素注射的升级。方法:这项回顾性现实世界研究分析了309名在初级保健中使用10或14天CGM(2020-2024)的成年T2D患者的数据。主要目的是评估CGM对治疗升级的影响,特别是对MDI的影响。次要目的是确定预测降糖治疗(GLT)强化的因素。结果:在309名参与者(中位年龄:65[56-73]岁,糖尿病病程:16[11-23]年,基线HbA1c: 8.6% [70 mmol/mol])中,基于CGM结果,91.3%被认为不适合MDI(非MDI GLT组,n = 282)。在该组中,经过14天的cgm后,76%的患者HbA1c-GMI差异达到了0.5%,54%的患者达到了1.0%。基础胰岛素使用略有下降(70%至64%,p = 0.13),而每日两次胰岛素使用增加(12%至18%,p = 0.02)。GLTs基本保持不变。结论:在91.3%控制不良的t2dm成人中,短期CGM可防止MDI升级,强化了其作为成本效益策略的作用。正如频繁的HbA1c-GMI差异所证明的那样,CGM可能改善了自我管理行为,反映了对高血糖的更好管理。这些发现强调了CGM在糖尿病护理中作为一种实用的行为和治疗工具。
{"title":"Short-term CGM as a tool to optimize glycemic control and defer intensive insulin therapy in people with poorly controlled type 2 diabetes: a Belgian real-life study.","authors":"Philippe Oriot, Linh Bui, Noémie Klipper Dit Kurz, Mirela Morisca Gavriliu, Maria-Claudia Negrea, Michel P Hermans","doi":"10.1080/17843286.2025.2528030","DOIUrl":"10.1080/17843286.2025.2528030","url":null,"abstract":"<p><strong>Objective: </strong>Continuous glucose monitoring (CGM) benefits type 2 diabetes (T2D) patients on multiple daily insulin injections (MDI), but its role in non-intensive insulin therapy remains underexplored. This study evaluates whether a short-term CGM non-blinded can postpone the escalation to multiple daily insulin injections in people with poorly controlled T2D.</p><p><strong>Methods: </strong>This retrospective real-world study analyzed data from 309 adults with T2D in primary care who used a 10 or 14-day CGM (2020-2024). The primary objective was to assess CGM's impact on therapy escalation, particularly to MDI. The secondary objective was to identify factors predicting the intensification of glucose-lowering therapy (GLT).</p><p><strong>Results: </strong>Among the 309 participants (median age: 65 [56-73] years, diabetes duration: 16 [11-23] years, baseline HbA1c: 8.6% [70 mmol/mol]), 91.3% were deemed unsuitable for MDI based on CGM results (non-MDI GLT group, <i>n</i> = 282). In this group, 76% achieved an HbA1c-GMI differential > 0.5%, and 54% >1.0% after 14 day-CGM. Basal insulin use decreased slightly (70% to 64%, <i>p</i> = 0.13), while twice-daily insulin increased (12% to 18%, <i>p</i> = 0.02). GLTs remained largely unchanged.</p><p><strong>Conclusion: </strong>A short-term CGM prevented MDI escalation in 91.3% of poorly controlled T2D adults, reinforcing its role as a cost-effective strategy. CGM likely improved self-management behaviors, as evidenced by frequent HbA1c-GMI differentials, reflecting better management of hyperglycemia. These findings highlight CGM as a practical behavioral and therapeutic tool in diabetes care.</p>","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"71-82"},"PeriodicalIF":0.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144551683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of a heat protocol with the Allplex HPV HR assay on the fully automated Seegene STARlet platform for detection of human papillomaviruses. 在全自动Seegene STARlet平台上对用于检测人乳头瘤病毒的Allplex HPV HR测定的热方案进行评估。
IF 0.9 4区 医学 Q2 Medicine Pub Date : 2025-08-01 Epub Date: 2025-08-13 DOI: 10.1080/17843286.2025.2546421
Vercaeren Cato, Kieffer Davy, Louwagie Annelies, Nijs An, Delvaux Sigrun, Strybol David, Pirens Tina, Petermans Stéphanie, Maurissen Wim, Steels Sophie

Objective: Cervical cancer, primarily caused by persistent infections with high-risk human papillomaviruses (hrHPV), remains a significant global health issue. Effective screening methods are essential for early detection and prevention. This study evaluates a novel 'heat protocol' (HP) for pre-treatment of cervical samples in SurePath medium in the detection of hrHPV using the Seegene Allplex HPV HR Assay on the fully automated Seegene STARlet platform.

Methods: 50 cervical samples from women aged 21-69 were collected between March 2024 and June 2025 during routine screening at Sint-Trudo Hospital. Samples were pre-treated using either the HP (95 °C for 55 minutes on the Seegene STARlet) or the validated LB method. All were tested using the Allplex HPV HR Assay. The Alinity m assay served as reference. Precision, accuracy, and method comparison were assessed using clinical and external quality control samples. Statistical analyses included kappa agreement, non-inferiority testing, and Bland-Altman analysis of Ct values. .

Results: Our findings demonstrate that the HP shows higher sensitivity (96%) than both the LB pre-treatment (93%) and the external reference method (Alinity m). The HP also identified additional HPV genotypes not detected by the other methods, suggesting improved detection of low viral loads. Ct values were on average lower with HP, which supports this increased sensitivity. A non-inferiority analysis confirmed that HP is not inferior to LB.

Conclusion: The study confirms that the new HP offers excellent precision, accuracy, and sensitivity. While the LB pre-treatment remains a viable alternative, the HP's efficiency, reduced hands-on time and improved sensitivity make it the preferred method for our routine clinical practice.

目的:宫颈癌主要由高危人乳头瘤病毒(hrHPV)持续感染引起,仍然是一个重大的全球健康问题。有效的筛查方法对于早期发现和预防至关重要。本研究在全自动Seegene STARlet平台上使用Seegene Allplex HPV HR Assay,评估了一种新的“热方案”(HP),用于在SurePath培养基中检测hrHPV的宫颈样本的预处理。方法:于2024年3月至2025年6月在st - trudo医院进行常规筛查,收集年龄在21-69岁的女性宫颈样本50例。样品使用HP(在Seegene STARlet上95 °C 55分钟)或经过验证的LB方法进行预处理。所有患者均采用Allplex HPV HR Assay进行检测。Alinity m测定法作为参考。精密度、准确度和方法比较采用临床和外部质量控制样品进行评估。统计分析包括kappa一致性、非劣效性检验和Bland-Altman Ct值分析。结果:我们的研究结果表明,HP比LB预处理(93%)和外部参考方法(Alinity m)具有更高的灵敏度(96%)。HP还发现了其他方法未检测到的其他HPV基因型,这表明低病毒载量的检测得到了改进。HP的Ct值平均较低,这支持了灵敏度的提高。一项非劣效性分析证实了HP并不逊于lb。结论:该研究证实了新的HP具有出色的精密度、准确度和灵敏度。虽然LB预处理仍然是一种可行的替代方法,但HP的效率、减少的操作时间和提高的灵敏度使其成为我们常规临床实践的首选方法。
{"title":"Evaluation of a heat protocol with the Allplex HPV HR assay on the fully automated Seegene STARlet platform for detection of human papillomaviruses.","authors":"Vercaeren Cato, Kieffer Davy, Louwagie Annelies, Nijs An, Delvaux Sigrun, Strybol David, Pirens Tina, Petermans Stéphanie, Maurissen Wim, Steels Sophie","doi":"10.1080/17843286.2025.2546421","DOIUrl":"10.1080/17843286.2025.2546421","url":null,"abstract":"<p><strong>Objective: </strong>Cervical cancer, primarily caused by persistent infections with high-risk human papillomaviruses (hrHPV), remains a significant global health issue. Effective screening methods are essential for early detection and prevention. This study evaluates a novel 'heat protocol' (HP) for pre-treatment of cervical samples in SurePath medium in the detection of hrHPV using the Seegene Allplex HPV HR Assay on the fully automated Seegene STARlet platform.</p><p><strong>Methods: </strong>50 cervical samples from women aged 21-69 were collected between March 2024 and June 2025 during routine screening at Sint-Trudo Hospital. Samples were pre-treated using either the HP (95 °C for 55 minutes on the Seegene STARlet) or the validated LB method. All were tested using the Allplex HPV HR Assay. The Alinity m assay served as reference. Precision, accuracy, and method comparison were assessed using clinical and external quality control samples. Statistical analyses included kappa agreement, non-inferiority testing, and Bland-Altman analysis of Ct values. .</p><p><strong>Results: </strong>Our findings demonstrate that the HP shows higher sensitivity (96%) than both the LB pre-treatment (93%) and the external reference method (Alinity m). The HP also identified additional HPV genotypes not detected by the other methods, suggesting improved detection of low viral loads. Ct values were on average lower with HP, which supports this increased sensitivity. A non-inferiority analysis confirmed that HP is not inferior to LB.</p><p><strong>Conclusion: </strong>The study confirms that the new HP offers excellent precision, accuracy, and sensitivity. While the LB pre-treatment remains a viable alternative, the HP's efficiency, reduced hands-on time and improved sensitivity make it the preferred method for our routine clinical practice.</p>","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"91-99"},"PeriodicalIF":0.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144843974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of the AIX1000 automated rapid plasma reagin test in a tertiary academic medical center. AIX1000自动快速血浆再生素试验在三级学术医疗中心的评价
IF 0.9 4区 医学 Q2 Medicine Pub Date : 2025-08-01 DOI: 10.1080/17843286.2025.2543336
Taeyang Chin, Elizaveta Padalko

Objectives: To evaluate the analytical performance of the automated AIX1000 RPR assay compared to the manual Macro-Vue RPR Card Test for syphilis monitoring in a high-prevalence, reverse screening setting.

Methods: Serum samples were tested using both AIX1000 and manual RPR in retrospective (n = 75) and prospective (n = 279) cohorts. Qualitative and quantitative concordance were assessed, along with AIX1000's accuracy, precision, specificity, carry-over, and freeze-thaw stability.

Results: In the retrospective cohort, overall qualitative agreement was 90.7% (κ = 0.80), with 77.3% of samples showing titers within one dilution. In the prospective cohort, qualitative agreement was 86.0% (κ = 0.72), with 90.7% of samples within one dilution. AIX1000 results were often 1-2 dilutions lower than manual RPR, especially in high-titer samples (≥1:16), where titer concordance (±1 dilution step) dropped to 38.7% (prospective) and 35.3% (retrospective). Accuracy analysis using external quality controls revealed a consistent one dilution-step bias for both assays: manual RPR read higher and AIX1000 lower, explaining the observed discrepancies. Analytical performance met predefined criteria: within and between runs were consistent, specificity showed no cross-reactivity, and no carry-over contamination was observed. Freeze-thaw testing had minimal effect on results.

Conclusion: The AIX1000 showed good concordance with manual RPR, particularly at lower titers, with reliable analytical performance and operational advantages. However, systematic titer underestimation compared to manual RPR, particularly in high-titer samples, may affect clinical interpretation if tests are transitioned. Clinicians should be informed of this discrepancy when transitioning platforms.

目的:评价自动化AIX1000 RPR检测与人工Macro-Vue RPR卡试验在高流行、反向筛查环境下梅毒监测中的分析性能。方法:采用AIX1000和手工RPR对血清样本进行回顾性(n = 75)和前瞻性(n = 279)检测。评估定性和定量一致性,以及AIX1000的准确性、精密度、特异性、携带性和冻融稳定性。结果:在回顾性队列中,总体定性一致性为90.7% (κ = 0.80), 77.3%的样品滴度在一个稀释度内。在前瞻性队列中,定性一致性为86.0% (κ = 0.72), 90.7%的样本在一次稀释内。AIX1000结果通常比手动RPR低1-2个稀释倍数,特别是在高滴度样品(≥1:16)中,其滴度一致性(±1个稀释步)降至38.7%(前瞻性)和35.3%(回顾性)。使用外部质量控制的准确性分析显示,两种分析方法都存在一致的一个稀释步骤偏差:手动RPR读数较高,AIX1000较低,这解释了观察到的差异。分析性能符合预定义的标准:运行内和运行之间是一致的,特异性显示没有交叉反应性,没有观察到携带污染。冻融试验对结果影响最小。结论:AIX1000与人工RPR具有较好的一致性,特别是在低滴度时,具有可靠的分析性能和操作优势。然而,与手工RPR相比,系统滴度低估,特别是在高滴度样品中,如果检测转换,可能会影响临床解释。临床医生在转换平台时应了解这一差异。
{"title":"Evaluation of the AIX1000 automated rapid plasma reagin test in a tertiary academic medical center.","authors":"Taeyang Chin, Elizaveta Padalko","doi":"10.1080/17843286.2025.2543336","DOIUrl":"10.1080/17843286.2025.2543336","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the analytical performance of the automated AIX1000 RPR assay compared to the manual Macro-Vue RPR Card Test for syphilis monitoring in a high-prevalence, reverse screening setting.</p><p><strong>Methods: </strong>Serum samples were tested using both AIX1000 and manual RPR in retrospective (<i>n</i> = 75) and prospective (<i>n</i> = 279) cohorts. Qualitative and quantitative concordance were assessed, along with AIX1000's accuracy, precision, specificity, carry-over, and freeze-thaw stability.</p><p><strong>Results: </strong>In the retrospective cohort, overall qualitative agreement was 90.7% (κ = 0.80), with 77.3% of samples showing titers within one dilution. In the prospective cohort, qualitative agreement was 86.0% (κ = 0.72), with 90.7% of samples within one dilution. AIX1000 results were often 1-2 dilutions lower than manual RPR, especially in high-titer samples (≥1:16), where titer concordance (±1 dilution step) dropped to 38.7% (prospective) and 35.3% (retrospective). Accuracy analysis using external quality controls revealed a consistent one dilution-step bias for both assays: manual RPR read higher and AIX1000 lower, explaining the observed discrepancies. Analytical performance met predefined criteria: within and between runs were consistent, specificity showed no cross-reactivity, and no carry-over contamination was observed. Freeze-thaw testing had minimal effect on results.</p><p><strong>Conclusion: </strong>The AIX1000 showed good concordance with manual RPR, particularly at lower titers, with reliable analytical performance and operational advantages. However, systematic titer underestimation compared to manual RPR, particularly in high-titer samples, may affect clinical interpretation if tests are transitioned. Clinicians should be informed of this discrepancy when transitioning platforms.</p>","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"83-90"},"PeriodicalIF":0.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144764346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment-resistant sleep apnea due to untreated hypothyroidism. 甲状腺功能减退症未经治疗导致的难治性睡眠呼吸暂停。
IF 0.9 4区 医学 Q2 Medicine Pub Date : 2025-08-01 Epub Date: 2025-07-03 DOI: 10.1080/17843286.2025.2528023
Marie Schouterden, Fransien Van Hende, Saartje Demolder, Pascal Borzée, Bertien Buyse, Alexandros Kalkanis, Dries Testelmans

Background: Sleep apnea is a common disorder characterized by recurrent episodes of upper airway obstruction or impaired respiratory drive, leading to disrupted sleep and significant cardiopulmonary consequences. While anatomical and neuromuscular factors are well-established contributors to obstructive sleep apnea (OSA), and central sleep apnea (CSA) is often linked to cardiac or neurological conditions, the impact of endocrine disorders, particularly hypothyroidism, is frequently overlooked.

Clinical presentation: We describe a case of severe sleep apnea that exhibited persistent sleep apnea (including obstructive, but also central and mixed events) under continuous positive airway pressure (CPAP) therapy. Clinical and biochemical findings confirmed profound hypothyroidism with myxedema. Thyroid hormone replacement therapy led to substantial clinical improvement, including weight loss, normalization of thyroid function, and a marked reduction in residual AHI after eight months.

Conclusion: This case highlights the need for increased awareness of hypothyroidism as a potential and reversible cause of treatment-resistant sleep apnea (TRSA). Thyroid hormone replacement therapy can lead to significant improvement, emphasizing the need for routine thyroid function screening in patients with sleep apnea.

背景:睡眠呼吸暂停是一种常见的疾病,其特征是反复发作的上气道阻塞或呼吸驱动受损,导致睡眠中断和严重的心肺后果。虽然解剖和神经肌肉因素是阻塞性睡眠呼吸暂停(OSA)的公认因素,而中枢性睡眠呼吸暂停(CSA)通常与心脏或神经系统疾病有关,但内分泌紊乱,特别是甲状腺功能减退症的影响经常被忽视。临床表现:我们描述了一个严重睡眠呼吸暂停的病例,在持续气道正压(CPAP)治疗下表现出持续性睡眠呼吸暂停(包括阻塞性,但也包括中枢和混合性事件)。临床及生化结果证实为重度甲状腺功能减退伴黏液性水肿。甲状腺激素替代治疗导致了显著的临床改善,包括体重减轻,甲状腺功能正常化,8个月后残留AHI明显降低。结论:本病例强调需要提高对甲状腺功能减退作为难治性睡眠呼吸暂停(TRSA)的潜在和可逆原因的认识。甲状腺激素替代疗法可显著改善,强调对睡眠呼吸暂停患者进行常规甲状腺功能筛查的必要性。
{"title":"Treatment-resistant sleep apnea due to untreated hypothyroidism.","authors":"Marie Schouterden, Fransien Van Hende, Saartje Demolder, Pascal Borzée, Bertien Buyse, Alexandros Kalkanis, Dries Testelmans","doi":"10.1080/17843286.2025.2528023","DOIUrl":"10.1080/17843286.2025.2528023","url":null,"abstract":"<p><strong>Background: </strong>Sleep apnea is a common disorder characterized by recurrent episodes of upper airway obstruction or impaired respiratory drive, leading to disrupted sleep and significant cardiopulmonary consequences. While anatomical and neuromuscular factors are well-established contributors to obstructive sleep apnea (OSA), and central sleep apnea (CSA) is often linked to cardiac or neurological conditions, the impact of endocrine disorders, particularly hypothyroidism, is frequently overlooked.</p><p><strong>Clinical presentation: </strong>We describe a case of severe sleep apnea that exhibited persistent sleep apnea (including obstructive, but also central and mixed events) under continuous positive airway pressure (CPAP) therapy. Clinical and biochemical findings confirmed profound hypothyroidism with myxedema. Thyroid hormone replacement therapy led to substantial clinical improvement, including weight loss, normalization of thyroid function, and a marked reduction in residual AHI after eight months.</p><p><strong>Conclusion: </strong>This case highlights the need for increased awareness of hypothyroidism as a potential and reversible cause of treatment-resistant sleep apnea (TRSA). Thyroid hormone replacement therapy can lead to significant improvement, emphasizing the need for routine thyroid function screening in patients with sleep apnea.</p>","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"115-122"},"PeriodicalIF":0.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144551684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lupus anticoagulant testing in Belgian laboratories: a comparison with the 2020 International Society on Thrombosis and Haemostasis Scientific and Standardization Committee (ISTH-SSC) guidelines. 比利时实验室狼疮抗凝血试验:与2020年国际血栓和止血科学与标准化委员会(ISTH-SSC)指南的比较
IF 1.6 4区 医学 Q2 Medicine Pub Date : 2025-06-01 Epub Date: 2025-06-17 DOI: 10.1080/17843286.2025.2519714
Benedicte Vanhove, Lieve Van Hoovels, Sylvia Broeders, Wim Coucke, Marco W J Schreurs, Carolien Bonroy, Sofie Schouwers, Robin Vanstokstraeten, Els Bailleul, Katrien M J Devreese

Objectives: We investigated lupus anticoagulant (LA) testing in Belgium and verified these findings against the 2020 International Society on Thrombosis and Haemostasis Scientific and Standardization Committee (ISTH-SSC) Guidelines.

Methods: A survey, interrogating pre- and post-analytical aspects of antiphospholipid antibodies, including LA analysis, was distributed to all Belgian laboratories (n = 111).

Results: About 66% of the laboratories responding to the entire survey (58%) performed LA analysis. About 78% used thrombocyte-free citrated plasma. Most (90%) used the combination of dilute Russell's viper venom time (dRVVT) and activated partial thromboplastin time (aPTT), performing dRVVT (82%) and aPTT (78%) if the screening test was prolonged. A variety of instrument/reagent combinations were used. Normal pooled plasma (PNP) for mixing tests was used by 83%, either commercially lyophilized (56%) or frozen (44%), mostly (98%) in a 1:1 PNP: patient plasma ratio. Interpretation was based on normalized clotting time ratio, using manufacturers' or own study data as cutoff values. About 61% gave a final conclusion. About 88% added comments, mainly (94%) with a positive result. All laboratories programmed a barring period after an initial positive result. About 66% performed LA detection in patients receiving direct oral anticoagulants, 74% after using sample pretreatment with active charcoal absorption. LA testing for vitamin K antagonists and heparin-treated patients was done by 54%, regardless of international normalized ratio (64%) or anti-FXa results (82%).

Conclusions: The survey shows adherence to ISTH-SSC guidelines, especially for sample preparation and test methodologies. Additional efforts are required to harmonize LA detection in anticoagulated patients and result interpretation.

目的:我们调查了比利时的狼疮抗凝血剂(LA)测试,并根据2020年国际血栓和止血科学与标准化委员会(ISTH-SSC)指南验证了这些发现。方法:调查,询问抗磷脂抗体分析前和分析后的方面,包括LA分析,分发到所有比利时实验室(n = 111)。结果:约66%的实验室对整个调查(58%)进行了LA分析。约78%的人使用无血小板的柠檬酸血浆。大多数(90%)使用稀释罗素毒蛇毒液时间(dRVVT)和活化部分凝血活素时间(aPTT)的组合,如果筛选试验延长,则执行dRVVT(82%)和aPTT(78%)。使用了多种仪器/试剂组合。用于混合试验的正常混合血浆(PNP)占83%,商业冻干(56%)或冷冻(44%),大多数(98%)采用1:1的PNP:患者血浆比例。解释是基于标准化的凝血时间比,使用制造商或自己的研究数据作为截止值。约61%的人给出了最终结论。约88%的人添加了评论,其中以正面评价为主(94%)。在最初的阳性结果之后,所有实验室都设定了一个限制期。在直接口服抗凝药物的患者中,约66%的患者进行了LA检测,74%的患者在使用活性炭吸附的样品预处理后进行了LA检测。维生素K拮抗剂和肝素治疗患者的LA检测占54%,无论国际标准化比率(64%)或抗fxa结果(82%)如何。结论:调查显示了ISTH-SSC指南的遵守,特别是样品制备和测试方法。需要额外的努力来协调抗凝患者的LA检测和结果解释。
{"title":"Lupus anticoagulant testing in Belgian laboratories: a comparison with the 2020 International Society on Thrombosis and Haemostasis Scientific and Standardization Committee (ISTH-SSC) guidelines.","authors":"Benedicte Vanhove, Lieve Van Hoovels, Sylvia Broeders, Wim Coucke, Marco W J Schreurs, Carolien Bonroy, Sofie Schouwers, Robin Vanstokstraeten, Els Bailleul, Katrien M J Devreese","doi":"10.1080/17843286.2025.2519714","DOIUrl":"10.1080/17843286.2025.2519714","url":null,"abstract":"<p><strong>Objectives: </strong>We investigated lupus anticoagulant (LA) testing in Belgium and verified these findings against the 2020 International Society on Thrombosis and Haemostasis Scientific and Standardization Committee (ISTH-SSC) Guidelines.</p><p><strong>Methods: </strong>A survey, interrogating pre- and post-analytical aspects of antiphospholipid antibodies, including LA analysis, was distributed to all Belgian laboratories (<i>n</i> = 111).</p><p><strong>Results: </strong>About 66% of the laboratories responding to the entire survey (58%) performed LA analysis. About 78% used thrombocyte-free citrated plasma. Most (90%) used the combination of dilute Russell's viper venom time (dRVVT) and activated partial thromboplastin time (aPTT), performing dRVVT (82%) and aPTT (78%) if the screening test was prolonged. A variety of instrument/reagent combinations were used. Normal pooled plasma (PNP) for mixing tests was used by 83%, either commercially lyophilized (56%) or frozen (44%), mostly (98%) in a 1:1 PNP: patient plasma ratio. Interpretation was based on normalized clotting time ratio, using manufacturers' or own study data as cutoff values. About 61% gave a final conclusion. About 88% added comments, mainly (94%) with a positive result. All laboratories programmed a barring period after an initial positive result. About 66% performed LA detection in patients receiving direct oral anticoagulants, 74% after using sample pretreatment with active charcoal absorption. LA testing for vitamin K antagonists and heparin-treated patients was done by 54%, regardless of international normalized ratio (64%) or anti-FXa results (82%).</p><p><strong>Conclusions: </strong>The survey shows adherence to ISTH-SSC guidelines, especially for sample preparation and test methodologies. Additional efforts are required to harmonize LA detection in anticoagulated patients and result interpretation.</p>","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"62-70"},"PeriodicalIF":1.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sjögren's disease with mixed cryoglobulinemia presenting as a hypertensive emergency with thrombotic microangiopathy: a diagnostic puzzle. Sjögren病合并混合冷球蛋白血症表现为高血压急诊伴血栓性微血管病:一个诊断难题。
IF 1.6 4区 医学 Q2 Medicine Pub Date : 2025-06-01 Epub Date: 2025-06-17 DOI: 10.1080/17843286.2025.2519713
Hanne Reynaert, Priyanka Koshy, Xavier Bossuyt, Katrien De Vusser, Kathleen J Claes

We describe the case of a 50-year old woman presenting with hypertension-associated thrombotic microangiopathy (TMA) and nephrotic syndrome as an unusual initial presentation of a cryoglobulinemic glomerulonephritis secondary to primary Sjögren's disease. This case first highlights the importance of a thorough and systemic work-up in patients with TMA, given the broad differential diagnosis and diagnostic complexity. When initial evaluation does not reveal an underlying cause and TMA parameters improve with blood pressure control, a diagnosis of hypertension-associated TMA may be considered. However, hypertension-associated TMA is often secondary to an underlying auto-immune or primary renal disease, warranting further investigation. In this case, kidney biopsy revealed a membranoproliferative glomerulonephritis with hyaline thrombi. Electron microscopy showed subendothelial electron dense deposits, and serum analysis confirmed the presence of mixed cryoglobulins, establishing the diagnosis of cryoglobulinemic glomerulonephritis. Primary Sjögren's disease was suspected based on positive anti-Ro60 and anti-Ro52 antibodies and supported by the presence of sicca symptoms, and was finally confirmed by a positive Schirmer's test. This case illustrates the diagnostic value of a kidney biopsy in identifying the underlying etiology of TMA and it also highlights the importance of considering cryoglobulinemia in the differential diagnosis of membranoproliferative glomerulonephritis.

我们描述的情况下,一个50岁的妇女提出与高血压相关的血栓性微血管病(TMA)和肾病综合征作为一个不寻常的初始表现为低温球蛋白血症肾小球肾炎继发于原发性Sjögren的疾病。考虑到TMA的广泛鉴别诊断和诊断的复杂性,本病例首先强调了对TMA患者进行全面和系统检查的重要性。当最初的评估没有揭示潜在的原因,TMA参数随着血压的控制而改善时,可以考虑高血压相关TMA的诊断。然而,高血压相关的TMA通常继发于潜在的自身免疫性或原发性肾脏疾病,需要进一步研究。本例肾活检显示膜增生性肾小球肾炎伴透明血栓。电镜显示内皮下电子致密沉积,血清分析证实存在混合冷球蛋白,确定冷球蛋白血症性肾小球肾炎的诊断。原发性Sjögren病是基于抗ro60和抗ro52抗体阳性,并有sicca症状支持,最终通过Schirmer试验阳性确诊。本病例说明了肾活检在确定TMA的潜在病因方面的诊断价值,同时也强调了在鉴别诊断膜增殖性肾小球肾炎时考虑冷球蛋白血症的重要性。
{"title":"Sjögren's disease with mixed cryoglobulinemia presenting as a hypertensive emergency with thrombotic microangiopathy: a diagnostic puzzle.","authors":"Hanne Reynaert, Priyanka Koshy, Xavier Bossuyt, Katrien De Vusser, Kathleen J Claes","doi":"10.1080/17843286.2025.2519713","DOIUrl":"10.1080/17843286.2025.2519713","url":null,"abstract":"<p><p>We describe the case of a 50-year old woman presenting with hypertension-associated thrombotic microangiopathy (TMA) and nephrotic syndrome as an unusual initial presentation of a cryoglobulinemic glomerulonephritis secondary to primary Sjögren's disease. This case first highlights the importance of a thorough and systemic work-up in patients with TMA, given the broad differential diagnosis and diagnostic complexity. When initial evaluation does not reveal an underlying cause and TMA parameters improve with blood pressure control, a diagnosis of hypertension-associated TMA may be considered. However, hypertension-associated TMA is often secondary to an underlying auto-immune or primary renal disease, warranting further investigation. In this case, kidney biopsy revealed a membranoproliferative glomerulonephritis with hyaline thrombi. Electron microscopy showed subendothelial electron dense deposits, and serum analysis confirmed the presence of mixed cryoglobulins, establishing the diagnosis of cryoglobulinemic glomerulonephritis. Primary Sjögren's disease was suspected based on positive anti-Ro60 and anti-Ro52 antibodies and supported by the presence of sicca symptoms, and was finally confirmed by a positive Schirmer's test. This case illustrates the diagnostic value of a kidney biopsy in identifying the underlying etiology of TMA and it also highlights the importance of considering cryoglobulinemia in the differential diagnosis of membranoproliferative glomerulonephritis.</p>","PeriodicalId":7086,"journal":{"name":"Acta Clinica Belgica","volume":" ","pages":"54-61"},"PeriodicalIF":1.6,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Acta Clinica Belgica
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1